ADIPOQ and metabolic dysfunction-associated steatohepatitis: Younossi et al. combined CK-18 with serum Adiponectin and serum Resistin, and reported AUROC of 0.908 (95% CI, 0.814–0.964), sensitivity of 95.45% and specificity of 70.21% for differentiating NASH from fatty liver disease [48].